EUVIMEDDécouvrir EUVIMED
Beobachtungsstudie

DAPAgliflozin‐Related Cardiac REverse Remodeling by 2D and 3D Echocardiography in OptiMally Treated HFrEF Patients: The DAPA‐REM Study

Nicola Amelotti, Valentina Mantegazza, Anna Garlaschè, Elisabetta Salvioni, Massimo Mapelli, Andrea Baggiano, Manuela Muratori, Irene Mattavelli, Mattia Chiesa, Rebecca Caputo, Gloria Tamborini, Piergiuseppe Agostoni and 1 more

Echocardiography · 2026

DOI: 10.1111/echo.70654 ↗

At a glance

Beobachtungsstudie in Echocardiography, 2026. Written by Nicola Amelotti and 12 co-authors. Institution: Centro Cardiologico Monzino, IRCCS, Milan, Italy. Major MEDLINE topics: Benzhydryl Compounds, Echocardiography, Echocardiography, Three-Dimensional, Glucosides. 39 references. Funded by: Italian Ministry of Health to Cardiologico Monzino IRCCS.

RésuméSubjectsRéférences bibliographiquesCiteRelated studies

Abstract (original language)

Purpose

Sodium‐glucose cotransporter‐2 inhibitors promote cardiac reverse remodeling in heart failure (HF), yet data integrating two‐dimensional and three‐dimensional echocardiography (2DE and 3DE, respectively) in optimally treated HFrEF populations are limited. This study aimed to evaluate heart chambers size and function by 2D/3DE after dapagliflozin initiation, and to explore whether baseline estimated glomerular filtration rate (eGFR) or myocardial fibrosis on cardiac magnetic resonance (CMR) influence reverse remodeling.

Methods

Seventy‐five patients with LVEF ≤40% on guideline‐directed therapy were prospectively enrolled. Echocardiographic and clinical data were collected at baseline and 6‐month follow‐up (6MFU) after introduction of dapagliflozin 10 mg daily. Sub‐analyses were performed according to eGFR (

Subjects

MeSH terms (MEDLINE)

Benzhydryl CompoundsEchocardiographyEchocardiography, Three-DimensionalGlucosidesHeart FailureSodium-Glucose Transporter 2 InhibitorsVentricular RemodelingAgedFemaleHumansMaleMiddle AgedHeart VentriclesProspective StudiesStroke VolumeTreatment Outcome

Author keywords

HFrEFSGLT2‐idapagliflozinheart failurereverse remodeling

Substances

Benzhydryl CompoundsdapagliflozinGlucosidesSodium-Glucose Transporter 2 Inhibitors

Authors and institutions

  • Centro Cardiologico Monzino, IRCCS, Milan, Italy.
  • Department of Clinical Sciences and Community Health, Cardiovascular Section, University of Milan, Milan, Italy.
  • Department of Biomedical, Surgical and Dental Sciences, University of Milan, Milan, Italy.

Funding

  • Italian Ministry of Health to Cardiologico Monzino IRCCS

Cite

APA

Amelotti, N., Mantegazza, V., Garlaschè, A., Salvioni, E., Mapelli, M., Baggiano, A., Muratori, M., Mattavelli, I., Chiesa, M., Caputo, R., Tamborini, G., Agostoni, P., & Pontone, G. (2026). DAPAgliflozin‐Related Cardiac REverse Remodeling by 2D and 3D Echocardiography in OptiMally Treated HFrEF Patients: The DAPA‐REM Study. Echocardiography. https://doi.org/10.1111/echo.70654

Vancouver

Amelotti N, Mantegazza V, Garlaschè A, Salvioni E, Mapelli M, Baggiano A, et al. DAPAgliflozin‐Related Cardiac REverse Remodeling by 2D and 3D Echocardiography in OptiMally Treated HFrEF Patients: The DAPA‐REM Study. Echocardiography. 2026. doi:10.1111/echo.70654

BibTeX
@article{Amelotti2026,
  author = {Amelotti, Nicola and Mantegazza, Valentina and Garlaschè, Anna and Salvioni, Elisabetta and Mapelli, Massimo and Baggiano, Andrea and Muratori, Manuela and Mattavelli, Irene and Chiesa, Mattia and Caputo, Rebecca and Tamborini, Gloria and Agostoni, Piergiuseppe and Pontone, Gianluca},
  title = {DAPAgliflozin‐Related Cardiac REverse Remodeling by 2D and 3D Echocardiography in OptiMally Treated HFrEF Patients: The DAPA‐REM Study},
  journal = {Echocardiography},
  year = {2026},
  doi = {10.1111/echo.70654}
}
Start for free →